Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06740526 · ClinicalTrials.gov registry record · Phase 2
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
A Phase 2 study of IgA Nephropathy, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 5
- Study locations
NCT06740526: Recruiting Phase 2 study of IgA Nephropathy, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT06740526 is a Phase 2 study of IgA Nephropathy that is actively recruiting participants, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 25 participants, below the 165-participant average among 10 other IgA Nephropathy trials with a reported enrollment target (85% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06740526, a Phase 2 study of IgA Nephropathy, is actively recruiting participants, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a phase 2b open-label trial to characterize histopathological biomarkers of disease in immunoglobulin A nephropathy (IgAN) and demonstrate potential changes in response to sibeprenlimab.
Conditions Studied
Interventions
- DRUG Sibeprenlimab
Study Locations (5)
Colorado
- Clinical Research Site 330 - Denver
Massachusetts
- Clinical Research Site 369 - Boston
South Dakota
- Clinical Research Site 374 - Dakota Dunes
Texas
- Clinical Research Site 324 - Houston
Ontario
- Clinical Research Site 305 - Scarborough Village
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-11-19 |
| Est. Completion | 2029-04-17 |
| Phase | Phase 2 |
What NCT06740526 shows while recruiting
NCT06740526 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 165-participant average among 10 other IgA Nephropathy trials with a reported enrollment target (85% lower).
The record links to 1 condition, with IgA Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which Sibeprenlimab is the first listed.
NCT06740526 lists 5 locations in 5 states (Colorado, Massachusetts, South Dakota).
Frequently Asked Questions
What is clinical trial NCT06740526 about?
NCT06740526 is a clinical study titled "Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue". This is a phase 2b open-label trial to characterize histopathological biomarkers of disease in immunoglobulin A nephropathy (IgAN) and demonstrate potential changes in response to sibeprenlimab.
What is the current status of trial NCT06740526?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2024-11-19. Estimated completion is 2029-04-17.
What conditions does trial NCT06740526 study?
This clinical trial studies the following conditions: IgA Nephropathy.
What interventions are being tested in trial NCT06740526?
The interventions under investigation include: Sibeprenlimab (DRUG).
Who is sponsoring clinical trial NCT06740526?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06740526 being conducted?
This trial has 5 study locations across Colorado, Massachusetts, South Dakota, Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgA Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06740526's enrollment target sits among peer trials
25 9th of 10 higher than 2 of 10 other IgA Nephropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other IgA Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Atrasentan in Patients With Proteinuric Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
COMPLETED · Phase 2
-
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
COMPLETED · Phase 2
-
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
COMPLETED · Phase 2
-
Study of BHV-1400 in IgA Nephropathy
RECRUITING · Phase 1
-
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI